Wanbury Limited expands API market reach with new regulatory submissions
Wanbury Limited, a leading pharmaceutical company specializing in domestic and global APIs and branded formulations, has announced the expansion of its regulatory submissions for various Active Pharmaceutical Ingredients (APIs). These moves target new international markets and operational milestones.The company provided details regarding the regulatory status of Diphenhydramine HCl, confirming that necessary filings have been submitted to both Malaysia and Singapore.
Furthermore, Wanbury Limited is planning market penetration for Paroxetine HCl in Korea and Latin America through strategic DMF submissions.
In an important operational update, the company confirmed receiving a formal audit report from MFDS (Korea FDA) concerning its Patalganga facility. The inspection conducted in April 2026 resulted in zero observations.
WANBURY Stock Price Movement
Wanbury Limited shares are rising to ₹263.6 as of 1:41 PM today, gaining 4.44% in live trading. The stock sees brisk activity with 119,176 shares traded during the current session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.